Dispatch Bio, co-founded by Carl June, MD, the Richard W. Vague Professor in Immunotherapy at Penn Medicine, is developing a cancer treatment platform that uses a virus to deliver an optimized universal antigen to tumor cells, effectively labeling them for subsequent targeting by CAR-T cells. The technology is intended to overcome a key limitation of current CAR-T cell therapies by broadening the range of tumors that can be targeted and treated. Learn more here and here. The company was also recently featured in Nature Biotechnology.